Copyright
©The Author(s) 2023.
World J Diabetes. Mar 15, 2023; 14(3): 234-254
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.234
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.234
Table 1 Primary and secondary antibodies
| Antibodies | Company | Dilution |
| CD31 | abcam, ab281583 | 1:300 dilution |
| α-SMA | abcam, ab124964 | 1:300 dilution |
| Caspase-1 | Servicebio, GB11383 | 1:500 dilution |
| Cleaved-caspase-1 | Immunoway, YC002 | 1:1000 dilution |
| NLRP3 | Immunoway, YT5382 | 1:1000 dilution |
| GSDMD | Proteintech, 66387-1-l g | 1:5000 dilution |
| ICAM-1 | abcam, ab222736 | 1:1000 dilution |
| VCAM-1 | abcam, ab134047 | 1:1000 dilution |
| eNOS | abcam, ab5589 | 1:1000 dilution |
| VEGF | abcam, ab52917 | 1:5000 dilution |
| CD45 | Proteintech, 60287-1-l g | 1:200 dilution |
| TNF-α | abcam, ab183218 | 1:1000 dilution |
| VE-cadherin | Proteintech, 27956-1-AP | 1:1000 dilution |
| β-catenin | Proteintech, 51067-2-AP | 1:5000 dilution |
| F4/80 | Servicebio, GB113373 | 1:500 dilution |
| iNOS | abcam, ab15323 | 1:250 dilution |
| Arg-1 | Proteintech, 66129-1-l g | 1:1000 dilution |
| Jagged-1 | Immunoway, YT5401 | 1:1000 dilution |
| Notch-1 | Servicebio, GB111690 | 1:500 dilution |
| ephrin-B2 | Immunoway, YT1586 | 1:1000 dilution |
| MMP9 | Servicebio, GB11132 | 1:1000 dilution |
| MMP2 | Servicebio, GB11130 | 1:1000 dilution |
| GAPDH | Servicebio, G3206-1OD | 1:2000 dilution |
| α-tubulin | Servicebio, GB15139 | 1:500 dilution |
| Goat anti-rabbit IgG | abcam, ab216777 | 1:5000 dilution |
| Goat anti-mouse IgG H&L | Abcam, ab216772 | 1:5000 dilution |
| Alexa Flour® 488 goat anti-rabbit IgG | Servicebio, GB25303 | 1:250 dilution |
| Cy3-conjugated goat | Servicebio, GB25303 | 1:250 dilution |
| anti-mouse IgG |
Table 2 Primer sequences
| Gene | Species | Forward sequence (5’-3’) | Reverse sequence (5’-3’) |
| PCNA | Mouse | GTCGGGTGAATTTGCACGTA | CTCTATGGTTACCGCCTCCTC |
| GAPDH | Mouse | CCTCGTCCCGTAGACAAAATG | TGAGGTCAATGAAGGGGTCGT |
| Jagged-1 | Human | TGTGGCTTGGATCTGTTGCTTGG | ACGTTGTTGGTGGTGTTGTCCTC |
| Notch-1 | Human | GTGCCCTGGGCTTCTCTG | GGCACGATTTCCCTGACCA |
| ephrin-B2 | Human | CGTCCAGAACTAGAAGCTGGT | CCGTCTGTGCTAGAACCTGG |
| VEGF | Human | ACAAATGTGAATGCAGACCAAA | ACCAACGTACACGCTCCAG |
| eNOS | Human | GCCGGAACAGCACAAGAGTTA | CCCTGCACTGTCTGTGTTACT |
| VE-Cadherin | Human | CAGCCCAAAGTGTGTGAGAA | CGGTCAAACTGCCCATACTT |
| β-catenin | Human | AGCTTCCAGACACGCTATCAT | CGGTACAACGAGCTGTTTCTAC |
| GAPDH | Human | GGAAGCTTGTCATCAATGGAAATC | TGATGACCCTTTTGGCTCCC |
- Citation: Gu JJ, Hou YL, Yan YH, Li J, Wei YR, Ma K, Wang XQ, Zhang JH, Wang DD, Li CR, Li DQ, Sun LL, Gao HL. Tongxinluo promotes endothelium-dependent arteriogenesis to attenuate diabetic peripheral arterial disease. World J Diabetes 2023; 14(3): 234-254
- URL: https://www.wjgnet.com/1948-9358/full/v14/i3/234.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i3.234
